Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2016Inflammatory Bowel Diseases

Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

Bruce E. SandsBruce E. SandsStatens Serum InstitutWilliam J. SandbornWilliam J. SandbornSemmelweis UniversityGert Van AsscheGert Van AsscheBrigham and Women's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sands et al. (2016) studied this question.

synapsesocial.com/papers/6a7e76e30ffa55711f4c4fa0https://doi.org/10.1097/mib.0000000000000979
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease2013 · 2,735 citations
  2. 2Review: Optimal use of biologics in the management of Crohn’s disease2010 · 40 citations